-
Kangtai Biological Partners with Bahrain Pharma Firm on Strategic Vaccine Production Agreement
•
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a prominent player in China’s biotechnology sector, has entered into a supply and production licensing agreement with a leading pharmaceutical company based in Bahrain. This partnership focuses on a range of vaccines, including the 13-valent pneumococcal polysaccharide conjugate vaccine, the 23-valent pneumococcal…
-
EMA’s CHMP Gives Green Light to Sanofi’s Fexinidazole for Acute Sleeping Sickness Treatment
•
Last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on Sanofi’s (NASDAQ: SNY) Fexinidazole Winthrop (fexinidazole) as a 10-day treatment for acute sleeping sickness caused by Trypanosoma brucei (T.b.) rhodesiense in both adults and children. The EMA is…
-
BGI Genomics Receives NMPA Approval for Innovative Colorectal Cancer Detection Kit
•
BGI Genomics Co., Ltd. (SHE: 300676), a leading genomics firm based in China, has announced the approval of its medical device license from the National Medical Products Administration (NMPA) for a novel gene methylation detection kit. The kit employs fluorescence PCR technology to assess the combined methylation status of the…
-
InventisBio’s KRAS G12C Inhibitor D-1553 Advances Toward Priority Review in China
•
According to the China Center for Drug Evaluation (CDE), Shanghai-based InventisBio Co., Ltd. (SHA: 688382) is on track to secure priority review status for its KRAS G12C inhibitor, D-1553, aimed at treating locally advanced or metastatic non-small cell lung cancer (NSCLC) with a confirmed KRAS G12C mutation, particularly in patients…
-
GSK’s CCO Calls China a Hotbed for Innovative Molecules and Licensing Deals
•
In an interview with the Financial Times, Luke Miels, Chief Commercial Officer of UK-based GlaxoSmithKline (GSK; NYSE: GSK), highlighted China as a key source of innovative molecules for licensing agreements. Miels attributes this trend to China’s robust chemistry capabilities and the willingness of local companies to out-license their rights: “You…
-
Biocytogen and Ona Therapeutics Forge Antibody Evaluation and Licensing Agreement
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), based in China, has entered into an antibody evaluation, option, and licensing agreement with Spain’s Ona Therapeutics. According to the terms of the agreement, Biocytogen will provide Ona with access to evaluate its proprietary RenMice-derived fully human antibodies targeting a specific tumor. Ona…
-
WuXi Biologics Partners with Visen Pharmaceuticals for Lonapegsomatropin Manufacturing
•
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into a partnership agreement with Visen Pharmaceuticals, a joint venture between Denmark’s Ascendis Pharma A/S (NASDAQ: ASND) and Chinese healthcare investment firm Vivo Capital. Under the terms of the deal, Visen Pharmaceuticals will entrust WuXi Biologics…
-
Keytruda Gains 12th Indication Approval in China for HER2-Negative Gastric Cancer
•
US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that its immunotherapy drug Keytruda (pembrolizumab) has received approval from the National Medical Products Administration (NMPA) in China for a new indication. The drug is now approved as a first-line treatment for locally advanced unresectable or metastatic HER2-negative…
